由上海士研（Shine Media）主办，美中药协、美国华人生物医药协会、百华协会共同协办的第三届生物制药中国发展国际峰会（BioChina International 2014）将在2014年9月25至26日于北京召开。
随着十二五规划以来国家对生物制药产业的大力扶持以及海归人才的不断回流，中国生物制药产业在过去几年一直保持高速增长。预计未来五年，中国生物制药产业将保持30%左右的年均增长速度，到2015年市场规模将超过4000亿人民币。跨国企业如罗氏、诺华等已陆续有生物药上市，布局中国市场，同时，国内外生物制药开发及上市合作也迎来了新一轮的高潮，诸如礼来与浙江贝达合作推进抗癌药物Vectibix在中国上市；辉瑞与浙江海正合作开发生物仿制药；华海药业与美国Oncobiologics 公司；浙江医药和美国AMBRX； 嘉和生物和韩国BIOCND等。此外，随着中信国健、百泰生物、丽珠集团、海正药业等一系列国产高科技单抗产品的陆续上市并有望进入国内医保范畴，未来五年将成为中国生物制药产业的黄金发展期。然而，在生物制药产业化的道路上，中国也面临着诸多挑战。
怎样将科研成果转化为可进行大规模生产的有效产品，怎样确保质量并符合法律规范？ 这些问题的关键在于生物工艺。工艺放大、小试生产、纯化、表达技术以及质量控制等都是关键因素。产业决策者在思考如何使中国生物制药步入新台阶时，应该重点考虑这些问题。除了生物工艺，中国正在尝试生物仿制药、新型疫苗及抗体的研发，从而扩大产品线。随着2015年全球大部分生物制药的专利到期，生物仿制药被公认为未来生物制药产业的绝佳机会及发展主流。 然而，不少业内人士提醒，面对庞大的生物仿制药市场，企业应该思考如何应对未来可能出现的激烈的市场竞争。
基于这样的背景，第三届生物制药中国发展国际峰会（BioChina International 2014）将邀请超过200位来自国内外知名生物制药企业、技术公司、科研院所及监管机构的专家、学者及产业领袖，从研发、投资、注册、生产、质量控制等多方面对中国生物制药产业目前的现状、面临的挑战及未来的发展趋势进行全面、深刻的解读。我们希望通过本次会议为国内外业内人士提供一个绝佳的学习、交流、合作平台，共同推动中国生物制药产业的快速、健康发展。
BioChina International 2014 Coming to Beijing
BioChina International 2014, supported by SAPA,CBA and Bayhelix, will be held on Sept. 25-26 at Beijing China.
With the strong government policy support, growing number of oversea talented returnees and huge market demand, China biopharma industry has achieved fast development during the past decade. As a result of regional partnership, a series of Gene-based drugs and mAbs enter the local market, dozens more are in clinical stage. A golden age for biopharma development is expected to arrive in the future five to ten years.
However, on the way to achieve biologic industrialization, China is faced with challenges in transforming good research into effective products that can be reproduced in large quantities and meet all regulatory and quality standards. The key to overcome above challenges lies in bioprocess. Advancements on scale-up, pilot production, purification, expression technologies, quality control etc are some key issues that the industry stakeholders need to take into consideration when working on strategies to bring China’s biopharma industry into the next level. Apart from challenges in bioprocess technologies, China is working toward to better biosimilar, novel vaccines and antibody R&D to fill limited product pipelines. With patent cliff for most of biologics in 2015, biosimilar has been recognized as great opportunities and major trends for future biopharma’s industry.
Riding on the booming biopharma industry in China, the inaugural BioChina International 2014 is positioned to be the largest biopharma conference in China to focus on latest industry development trend and partnership models, bioprocess, R&D advancement in China and globally. The content rich conference aims to build a definitive platform for biopharma industry leaders to gain proven strategies and solutions, on finding new finding new targets for pipeline expansion, establishing development partnership, scaling up both upstream and downstream processes, advancing cell line development, improving quality for biologics.
